Search company, investor...

Founded Year



Other Investors | Alive

About Biocam

BIOCAM develops and markets systems in the field of photodynamic detection, fluorescence diagnosis and videodermoscopy. With its multifunctional products DYADERM and DermoGenius BIOCAM is leading in skin cancer detection.

Headquarters Location

Friedenstrasse 30



Missing: Biocam's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biocam's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biocam

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biocam is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Biocam News

Biocam’s Revolutionary Endoscopy Solution Secures Them PLN 5M from NCBR

Oct 31, 2021

Biocam’s Revolutionary Endoscopy Solution Secures Them PLN 5M from NCBR Biocam’s Revolutionary Endoscopy Solution Secures Them PLN 5M from NCBR Biocam plans to have the product ready for the markets by 2024. The company is convinced that the telemedical nature of Biocam’s endoscopy capsules will ensure the solution’s success in a post-COVID world. Polish medtech Biocam announced that they successfully raised a PLN 5M grant from the Polish National Research and Development Center (NCBR) . This amount is NCBR’s contribution to the development of Biocam’s new endoscopy capsule that is due to hit both Polish and European markets in 2024. Why Biocam’s Endoscopy Is Better Jakub Niemczuk, Co-Founder and CTO at Biocam ITKeyMedia already wrote about Biocam’s technology and competitive advantages, and the company’s co-founder Jakub Niemczuk explained it in more detail in a podcast for ITKeyMedia. In a nutshell, Biocam’s revolutionary solution is a capsule that a patient swallows and has their gastrointestinal tract studied remotely. It has several clear advantages over the currently widespread methods – gastroscopy and colonoscopy: These methods are invasive, and are bound with a risk of perforation, causing patients discomfort. This is the main reason why patients are reluctant to undergo these procedures. Biocam’s capsules have a better reach, while traditional tube-based methods always have blind spots. Biocam employs a proprietary AI that spots anomalies in the gastrointestinal tract. It means that it only gives the doctor the images with anomalies, thus speeding up and facilitating the doctor’s job. A capsule can be used not only for collecting images but also as a delivery vehicle. Adding to these advantages, Biocam’s capsule costs about the same as a regular gastrointestinal study (narcosis+gastroscopy+colonoscopy) and twice cheaper than existing capsule solutions. Hence, it has a better chance of getting included in healthcare plans. Why Investors Choose to Work with Biocam Tomasz Jastrzębski, Founder and Managing Partner at LT Capital Tomasz Jastrzębski , partner at LT Capital , Biocam’s investor from a previous round, lists three things that his company takes into account when choosing startups for their portfolio: team, tech, and TAM (Total Addressable Market), and he is convinced that Biocam has it all. ’We invest at a very early stage, often the first institutional investor in the company. The team is always extremely important, but even more so at such an early stage. We believe that a technological advantage can drive a sustainable competitive advantage. We are looking for companies that utilize state-of-the-art AI and are enabling the 4th industrial revolution. Finally, the team should aim to disrupt a market that is big enough and will grow in the future,’ Mr Jastrzębski explains. According to him, even though LT Capital is a Bridge Apha fund and cannot make follow-on investments, it is eager to support its portfolio companies in obtaining further rounds of financing from both Polish and international funds. It is left to assume that LT Capital used its connections to help Biocam secure the current grant. NCBR’s Funding Comes with Footnotes However, the grant comes with a couple of conditions. First of all, it presupposes that the company co-funds the project with PLN 2M of its own funds. To complete the project, the startup plans to conduct another round of investment by the end of 2021 and raise another EUR 1M. Maciej Wysocki, Co-Founder and CEO at Biocam Besides, according to the company’s CEO Maciej Wysocki , such grants are not flexible when it comes to changing assumptions and costs.‘It does not take into account any remuneration outside the engineering team, including the costs related to project management, marketing, operations, and precisely implementation activities,’ Mr Wysocki tells ITKeyMedia. Additionally, Biocam recently acquired an angel investor, Marcin Grabski of Hydro Aparatura , who became interested in the company after publications in the media, tested the technology, and believed in its potential. According to Mr Wysocki, the parties finalized the transaction only in a few weeks. The Future of Biocam’s Endoscopy Solution Biocam’s CEO emphasizes that the telemedical nature of their capsules will become a decisive advantage when the product finally hits the markets. According to Deloitte , COVID accelerated the digitization of the healthcare system by at least a decade, and by 2030 Europe will lack over 4 million medical workers. According to Mr Wysocki’s information, over 50% less gastroscopy and colonoscopy were performed (as well as diagnostic tests from other fields of medicine) in 2020. Due to the isolation and overloading of the healthcare system, the access to preventive diagnostics and screening tests was limited. ‘It creates a kind of social health debt that we will be paying back as a society for another 5-10 years,’ he adds. That’s why, Mr Wysocki is convinced that even when the pandemic is over, home and remote diagnostic examinations are the natural future of medicine and can relieve the overloaded healthcare system.

Biocam Frequently Asked Questions (FAQ)

  • When was Biocam founded?

    Biocam was founded in 1998.

  • What is Biocam's latest funding round?

    Biocam's latest funding round is Other Investors.

  • Who are the investors of Biocam?

    Investors of Biocam include KfW, BayBG and S-REFIT Regionaler Finanzierungsfonds fur Innovationen und Technologieunternehmen.

  • Who are Biocam's competitors?

    Competitors of Biocam include Ikonisys, Senseonics, Stage I Diagnostics, Micrima, Orison and 10 more.

Compare Biocam to Competitors


Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.


Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Stage I Diagnostics Logo
Stage I Diagnostics

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.

Nanoprobes Logo

Nanoprobes was founded to develop the most sensitive reagents and technology for detecting biological molecules. The company's gold labeling technology uses chemically cross-linked metal clusters and nanoparticles as labels. Unlike conventional immunogold probes, in which colloidal gold particles are electrostatically adsorbed to antibodies and proteins, the company's gold labels are uncharged molecules which are cross-linked to specific sites on biomolecules. This aims to give the company's probes a range and versatility which is not available with colloidal gold. The company's labels can be attached to any molecule with a reactive group -- proteins, peptides, oligonucleotides, small molecules and lipids -- for detection and localization. Other labels can be combined with the company's gold labels; the company's FluoroNanogold probes combine Nanogold and fluorescein into a single probe for imaging a specimen both by fluorescence and electron microscopy. New probes can be engineered based on any fragment of a naturally occurring biomolecule, and the label can be positioned away from the binding site so it does not interfere with binding. The company's 1.4 nm Nanogold probes have been cited in over 80 publications, and the company are now developing larger cross-linkable labels in order to offer the company's customers larger covalently linkable probes with the same advantages.

Real Imaging

Real Imaging is developing an imaging solution for breast cancer detection which is both accurate and patient-friendly. Real imaging's MIRA technology will increase correct detection rates and decrease the amount of false diagnoses for women of all ages around the globe.

Microwave Imaging System Technologies (MIST)

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.